Chiral separation of β-adrenergic blockers in human plasma by SPE-HPLC

Chromatographia

Volumn 73, Issue 3-4, 2011, Pages 251-256

  Ali, Imran ^a   Al Othman, Zeid A ^b   Hussain, Afzal ^a   Saleem, Kishwar ^a   Aboul Enein, Hassan Y ^c  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Adrenergic blockers; Chiral separation; Column liquid chromatography; Human plasma; Plasma protein bindings; Solid phase extraction; SPE chiral HPLC

Indexed keywords

ALPRENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARAZOLOL; METOPROLOL; OXPRENOLOL;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; ELUTION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PLASMA; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

EID: 79951769490     PISSN: 00095893     EISSN: 16121112     Source Type: Journal    
DOI: 10.1007/s10337-010-1891-4     Document Type: Article

References (21)

1. I Ali VD Gaitonde HY Aboul-Eneinc A Hussaina 2009 Talanta 78 458 463 1:CAS:528:DC%2BD1MXhs1Omsbk%3D 10.1016/j.talanta.2008.11.043
2. Meyers EH, Jawetz E, Goldheim AA (1980) Review of medical pharmacology. Lange Medical Publication, USA
3. T Walle UK Walle MJ Wilson TC Fagan TE Gaffney 1984 Br J Clin Pharmacol 18 741 748 1:CAS:528:DyaL2MXhtVGls7c%3D
4. MG Schmid O Gecse Z Szabo F Kilar G Gubitz I Ali 2001 J Liq Chromatogr Relat Technol 24 2493 2504 1:CAS:528:DC%2BD3MXnsV2jtLo%3D 10.1081/JLC-100105955 (Pubitemid 32937353)
5. EJ Lee KM William 1990 Clin Pharmacokinet 18 339 345 1:CAS:528: DyaK3cXkslSnur4%3D 10.2165/00003088-199018050-00001
6. WL Nelson TR Burke 1978 Res Commun Chem Pathol Pharmacol 21 77 85 1:CAS:528:DyaE1cXlsFOisLw%3D
7. AM Barrett VA Cullum 1968 J Pharmacol 20 911 915 1:CAS:528: DyaF1MXjs1ehsA%3D%3D
8. K Balmer PO Lagerstrom BA Persson G Schill 1992 J Chromatogr A 592 331 337 1:CAS:528:DyaK38XhvFSnsrc%3D 10.1016/0021-9673(92)85104-2
9. CV Ram 2008 Am J Cardiol 102 242 244 10.1016/j.amjcard.2008.02.037
10. Belknap S (2008) Evid Based Med 13:50
11. V Cherezov DM Rosenbaum MA Hanson SGF Rasmussen FS Thian TS Kobilka HJ Choi P Kuhn W Weis BK Kobilka RC Stevens 2007 Science 318 1258 1265 1:CAS:528:DC%2BD2sXhtlGmur7I 10.1126/science.1150577 (Pubitemid 350172884)
12. FDA policy statement for the development of new stereoisomeric drugs, Publication date: 05/01/1992
13. Aboul-Enein HY, Ali I (2003) Chiral separation by liquid chromatography and related technologies. Marcel Dekker, USA
14. Health Canada (2000) stereochemical issues in chiral drug development. Health Canada guidance documents, http://www.hc-sc.gc.ca
15. R Shimazawa N Nagai S Toyoshima H Okuda 2008 J Health Sci 54 23 29 10.1248/jhs.54.23 (Pubitemid 351757436)
16. M Chamsaz S Asadpour AS Yazdi J Ghasemi 2009 J Iran Chem Res 2 1 21
17. I Ali VK Gupta HY Aboul-Enein A Hussain 2008 J Sep Sci 31 2040 2053 1:CAS:528:DC%2BD1cXos1equ7g%3D 10.1002/jssc.200800123 (Pubitemid 352003187)
18. PM Cerqueira EJ Cesarino C Bertucci PS Bonato VL Lanchote 2003 Chirality 15 542 549 1:CAS:528:DC%2BD3sXltFeisr4%3D 10.1002/chir.10244 (Pubitemid 36736619)
19. Y Okamoto E Yashima 1998 Angew Chem Int 37 1020 1043 10.1002/(SICI)1521- 3773(19980504)37:8<1020::AID-ANIE1020>3.0.CO;2-5
20. I Ali K Kummerer HY Aboul-Enein 2006 Chromatographia 63 295 307 1:CAS:528:DC%2BD2sXhs1yiur4%3D 10.1365/s10337-006-0762-5
21. F Albani R Riva M Contin A Baruzzi 1984 Br J Clin Pharmacol 18 244 246 1:CAS:528:DyaL2cXlsVemsLs%3D